Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2005-02-10
2008-10-28
Weber, Jon (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S012200, C530S350000, C530S324000, C435S039000, C435S810000
Reexamination Certificate
active
07442681
ABSTRACT:
The present invention provides a method of regulating vascular permeability. A peptide inhibitor of p21-activated kinase has been found to inhibit the increase in vascular permeability induced by several factors. The present invention further provides methods of identifying regulators of vascular permeability. This peptide or other p21-activated kinase inhibitors should therefore be useful to treat disorders where vascular leak is a contributing factor.
REFERENCES:
patent: 6248549 (2001-06-01), Van Eyk et al.
patent: 2004/0138133 (2004-07-01), Cheresh et al.
Kiosses et al. A Role for p21-Activated Kinase in Endothelial Cell Migration, Nov. 15, 1999, The Journal of Cell Biology, vol. 147, No. 4, pp. 831-843.
Dudek et al. Cytoskeletal regulation of pulmonary vascular permeability, 2002, J. Appl. Physiol., vol. 91, pp. 1487-1500.
Galisteo et al. The Adaptor Protein Nck Links Receptor Tyrosine Kinase with the Serine-Threonine Kinase Pak1, Aug. 30, 1996, The Journal of Biological Chemistry, vol. 271, No. 35, pp. 20997-21000.
Bokoch et al. Interaction of the Nck Adapter Protein with p21-activated Kinase (PAK), Oct. 18, 1996, The Journal of Biological Chemistry, vol. 217, No. 42, pp. 25746-25749.
Schwarze et al. In Vivo Protein Transduction: Delivery of a Biologically Active Protein into the Mouse, Sep. 3, 1999, Science, vol. 285, pp. 1569-1572.
Kioses, W.B., et al., “A Dominant-Negative p65 PAK Peptide Inhibits Angiogenesis”, Circulation Research, 2002, vol. 90(6), pp. 697-702.
Stockton, R.A., et al., “p21-activated Kinase Regulates Endothelial Permeability through Modulation of Contractility”, The Journal of Biological Chemistry, 2004, vol. 45(5), pp. 46621-46630.
Gute, D.C., et. al., “Inflammatory Responses to ischemia and reperfusion in skeletal muscle,” Mol Cell Biochem, vol. 179 ( No. 1-2), p. 169-87, (1998).
Edwards, S.L., “Tissue viability: understanding the mechanisms of injury and repair,” Nurs Stand, vol. 21 (13), p. 48-56; quiz 58, (2006).
Paul, R., et. al., “Src deficiency or blockade of Src activity in mice provides cerebral protection following stroke”, Nat. Med., vol. 7, p. 222-227 (2001).
Weis, S., et. al., “Src blockade stabilizes a Flk/cadherin complex, reducing edema and tissue injury following myocardial infarction”, J. Clin. Invest., vol. 113, p. 885-894, (2004).
Orfanos, S.E., et. al., “Pulmonary endothelium in acute lung injury: from basic science to the critically ill”, Intensive Care Med., vol. 30(9), p. 1702-14, (2004).
Esper, A.M., et. al., “Evolution of treatments for patients with acute lung injury”, Expert Opin. Investig. Drugs, vol. 14(5), p. 633-45, (2005).
Marx, G., “Fluid therapy in sepsis with capillary leakage”, Eur. J. Anaesthesiol., vol. 20(6), p. 429-42 (2003).
Demling, R.H., “The burn edema process: current concepts”, J. Burn Care Rehabil., vol. 26(3), p. 207-27, (2005).
Taber's Cyclopedic Medical Dictionary, Edition 20, pp. 118, 1640, 2005.
Murohara, T., et. al., “Vascular Endothelial Growth Factor/Vascular Permeability Factor Enhances Vascular Permeability Via Nitric Oxide and Prostacyclin”, Circulation Journal of the American Heart Association, 1998;97; pp. 99-107.
Connolly, D., et. al., “Tumor Vascular Permeability Factor Stimulates Endothelial Cell Growth and Angiogenesis”, J. Clin. Invest., Nov. 1989, pp. 1470-1478.
Eliceiri, Brian P., et. al., “Selective Requirement for Src Kinases during VEGF-Induced Angiogenesis and Vascular Permeability”, Molecular Cell., vol. 4, Dec. 1998, pp. 915-924.
Streit, M., et. al., “Thrombospondin-1 Suppresses Wound Healing and Granulation Tissue Formation in the Skin of Transgenic Mice”, The EMBO Journal, vol. 19, pp. 3272-3282, 2000.
Mundel, T., et. al., “Type IV Collagen-Derived Angiogenesis Inhibitors”, Science Direct, Microvascular Research, 2007, vol. 74, pp. 85-89.
Brinkmann, V., et. al., Pulmonary and Vascular Pharmacology of Sphingosine 1-Phosphate, Current Opinion in Pharmacology, 2006, vol. 6, pp. 244-250.
Skoura, A., et. al., “Essential Role of Sphingosine 1-Phosphate Receptor 2 in Pathological Angiogenesis of the Mouse Retina”, The Journal of Clinical Investigation, vol. 117, No. 9, pp. 2506-2516, Sep. 2007.
M. Oo, et. al., “Immunosuppressive and Anti-Angiogenic Sphingosine 1-Phosphate Receptor-1 Agonists Induce Ubiquitinylation and Proteasomal Degradation of the Receptor”, Journal of Biological Chemistry, vol. 282, No. 12, pp. 9082-9089, Mar. 23, 2007.
Schwartz Martin A.
Stockton Rebecca A.
Mohamed Abdel A
Schwegman Lundberg & Woessner, P.A.
University of Virginia Patent Foundation
Weber Jon
LandOfFree
Method of inhibiting vascular permeability does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of inhibiting vascular permeability, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of inhibiting vascular permeability will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3993151